Printer Friendly

POSSIS RECEIVES IDE APPROVAL FROM FDA

 MINNEAPOLIS, Dec. 16 /PRNewswire/ -- Possis Corporation (NASDAQ: POSS) announced today that Possis Medical, Inc. (PMI), its wholly owned subsidiary, has received conditional IDE approval from the U.S. Food and Drug Administration for its peripheral AngioJet(TM) thrombectomy system, a unique device initially intended for the percutaneous removal of blood clots occurring in peripheral (leg) arteries and vascular grafts. PMI plans to begin human clinical trials in the United States after obtaining necessary IRB approvals and finalizing arrangements with clinical investigators. Future AngioJet products will treat coronary artery and bypass graft thrombosis.
 IDE approval is a major step toward PMI's goal of bringing to market a family of AngioJet products designed to treat vascular thrombosis, a leading cause of death and disability, due to heart attacks, strokes, pulmonary failure and limb amputation. The AngioJet system consists of a non-disposable drive console and a disposable catheter, high pressure pump and accessories. AngioJet produces fine saline streams from openings located in the catheter's tip to wash thrombus from the blood vessel's wall, break it into small particles, draw these particles into the catheter's tip, and propel the particles down the catheter and out of the body.
 PMI believes its AngioJet products will become important therapeutic tools for treating peripheral and coronary vascular thrombosis. Taken together with PMI's IDE-approved Perma-Flow(R) coronary and Perma- Seal(TM) A-V fistula Vascular grafts, and with its marketed pacemaker leads, PMI is becoming further established as a provider of pioneering devices for treating vascular and cardiovascular disease.
 -0- 12/16/92
 /CONTACT: Robert G. Dutcher, president of Possis Medical, 612-550-1010/
 (POSS)


CO: Possis Medical, Inc.; Possis Corporation ST: Minnesota IN: MTC SU:

AL -- MN011 -- 7798 12/16/92 14:19 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 16, 1992
Words:284
Previous Article:JACOBS BUILDS MAJOR MTBE PRODUCTION UNIT FOR CHEVRON USA
Next Article:ARCH ANNOUNCES ACQUISITIONS
Topics:


Related Articles
POSSIS MEDICAL RECEIVES FDA APPROVAL FOR IDE APPLICATION
POSSIS MEDICAL FILES INVESTIGATIONAL DEVICE EXEMPTION APPLICATION
CARDIOPULMONICS REPORTS PMA SUBMISSION
CRYOLIFE, INC. GRANTED FDA APPROVAL TO EXPAND IMPLANT PROGRAM FOR HUMAN ALLOGRAFT HEART VALVES
FDA APPROVES I.D.E. FOR PROCEDURE USED TO TREAT AIDS
POSSIS MEDICAL FILES 510(k) AND IDE APPLICATIONS AND RECEIVES SECOND U.S. PATENT FOR ANGIOJET RAPID THROMBECTOMY SYSTEM
POSSIS MEDICAL, INC. RECEIVES FDA APPROVAL FOR PHASE 2 STUDY OF ANGIOJET CORONARY THROMBECTOMY SYSTEM
Possis Medical Inc. Moves Toward U.S. Marketing Clearance For AngioJet
Possis Medical Obtains Humanitarian Designation for Its Perma-Flow Graft
Possis Medical, Inc. Seeks FDA Approval to Begin Stroke Clinical Trial with the AngioJet System

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters